COMPARISON
Terlipressin vs Vosoritide
5 attributes held for at least one of the two. 5 differ. Each value carries the register it came from and the date that register was read.
Answer
Terlipressin is authorised or registered in 8 and Vosoritide in 7 of the 10 registers read. Terlipressin: highest phase Phase 3 (2 phase 3 trials, 0 with posted results). Vosoritide: highest phase Phase 3 (3 phase 3 trials, 0 with posted results). 0 registered trials include both.
States no view on which is preferable, safer or more effective. Not medical advice.
| Terlipressin | Vosoritide | |
|---|---|---|
| Registered trials differs | 118 clinicaltrials.gov · 2026-10-03 | 23 clinicaltrials.gov · 2026-10-03 |
| FDA label differs | FDA-approved: Terlivaz openfda · 2026-10-03T17:23:44.062Z | FDA-approved: VOXZOGO 0.4mg openfda · 2026-10-03T17:23:44.062Z |
| EU authorisation differs | Nothing on record ema read 2026-08-31 | Authorised ema · 2026-10-03 |
| EU authorised on differs | Not checked no record of "authorisedOn" for terlipressin | 2021-08-26 ema · 2026-10-03 |
| ATC code differs | Not checked no record of "atcCode" for terlipressin | M05BX ema · 2026-10-03 |
SIDE EFFECTS
Most common side effects, each beside its own placebo
| Side effect | Terlipressin | placebo | Vosoritide | placebo |
|---|---|---|---|---|
| Abdominal pain | 21.8% | 13.4% | - | - |
| Diarrhoea | 16.4% | 5.7% | - | - |
| Nausea | 15.0% | 11.3% | - | - |
| Dyspnoea | 12.3% | 6.7% | - | - |
| Hypotension | 11.3% | 6.7% | - | - |
| Respiratory failure | 10.5% | 3.0% | - | - |
| Vomiting | 8.9% | 7.2% | - | - |
| Hypokalaemia | 8.9% | 6.2% | - | - |
| Hepatic encephalopathy | 8.5% | 11.3% | - | - |
| Fluid overload | 8.2% | 4.1% | - | - |
| Injection site reaction | - | - | 79.1% | 40.6% |
| Injection site erythema | - | - | 76.7% | 40.6% |
| Viral infection | - | - | 18.6% | 12.5% |
| Injection site swelling | - | - | 18.6% | 6.3% |
| Fall | - | - | 16.3% | 9.4% |
| Injection site urticaria | - | - | 14.0% | 3.1% |
| Arthropod bite | - | - | 14.0% | 6.3% |
| Injection site induration | - | - | 11.6% | 0.0% |
| Constipation | - | - | 11.6% | 6.3% |
| Rhinitis | - | - | 9.3% | 0.0% |
Trial register Terlipressin: 2 placebo-controlled trials; Vosoritide: 1. Each peptide is compared with placebo in its own trials, not with the other: a dash means the event is not in that peptide's top list. Terlipressin side effects · Vosoritide side effects
LEGAL STATUS
Approval in each country read
| Country | Terlipressin | Vosoritide | Register |
|---|---|---|---|
| United States | FDA-approved | FDA-approved | Regulator FDA |
| European Union | Not on the register | Authorised | Regulator EMA |
| United Kingdom | Authorised | Not on the register | Regulator MHRA |
| Canada | Not on the register | Authorised | Regulator Health Canada |
| Australia | Registered | Registered | Regulator TGA |
| Switzerland | Authorised | Authorised | Regulator Swissmedic |
| Brazil | Registado | Registado | Regulator ANVISA |
| Serbia | Authorised | Not on the register | Regulator ALIMS |
| Singapore | Registered | Not on the register | Regulator HSA |
| Turkey | Ruhsatli | Ruhsatli | Regulator TITCK |
Values reproduce public registers on the dates shown. This comparison states no view on which compound is preferable, safer or more effective. Not medical, legal or regulatory advice.
WEEKLY
Register Watch, weekly
New trials, approvals and enforcement actions. One email a week.